Iambic Therapeutics
Founded Year
2019Stage
Series B - II | AliveTotal Raised
$206.23MLast Raised
$50M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-52 points in the past 30 days
About Iambic Therapeutics
Iambic Therapeutics focuses on drug discovery using an AI (artificial intelligence)-driven platform within the pharmaceutical industry. The company specializes in designing optimized medicines by using physics-based AI algorithms to explore chemical space and develop novel mechanisms of action. It primarily serves the healthcare sector by targeting unmet patient needs with its pipeline of therapeutic programs. Iambic Therapeutics was formerly known as Entos. It was founded in 2019 and is based in San Diego, California.
Loading...
Loading...
Research containing Iambic Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Iambic Therapeutics in 5 CB Insights research briefs, most recently on Mar 11, 2025.
Dec 3, 2024 report
Digital Health 50: The most promising digital health startups of 2024
Jul 2, 2024 team_blog
How to buy AI: Assessing AI startups’ potential
Expert Collections containing Iambic Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Iambic Therapeutics is included in 6 Expert Collections, including Digital Health.
Digital Health
11,305 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI 100 (2024)
100 items
Artificial Intelligence
7,221 items
Digital Health 50
50 items
AI in drug discovery
504 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Iambic Therapeutics Patents
Iambic Therapeutics has filed 7 patents.
The 3 most popular patent topics include:
- energy recovery
- ventilation
- air pollution control systems
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/24/2020 | 3/25/2025 | Ventilation, Energy recovery, Engine technology, Engine components, Air pollution control systems | Grant |
Application Date | 1/24/2020 |
|---|---|
Grant Date | 3/25/2025 |
Title | |
Related Topics | Ventilation, Energy recovery, Engine technology, Engine components, Air pollution control systems |
Status | Grant |
Latest Iambic Therapeutics News
Mar 25, 2025
HC Wainwright 2nd Annual AI-Based Drug Discovery Conference - April 2, 2025 Needham 24th Annual Healthcare Conference - April 7-10, 2025 Piper Sandler Spring Biopharma Symposium - April 16-17, 2025 Bank of America Healthcare Conference - May 13-15, 2025 About Iambic Founded in 2019 and headquartered in San Diego, California, Iambic is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform is delivering high-quality, differentiated therapeutics to the clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's architecture improves data efficiency and allows molecular models to venture across the space of chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. View source version on businesswire.com: https://www.businesswire.com/news/home/20250325119042/en/ Contacts media@iambic.ai
Iambic Therapeutics Frequently Asked Questions (FAQ)
When was Iambic Therapeutics founded?
Iambic Therapeutics was founded in 2019.
Where is Iambic Therapeutics's headquarters?
Iambic Therapeutics's headquarters is located at 5627 Oberlin Drive, San Diego.
What is Iambic Therapeutics's latest funding round?
Iambic Therapeutics's latest funding round is Series B - II.
How much did Iambic Therapeutics raise?
Iambic Therapeutics raised a total of $206.23M.
Who are the investors of Iambic Therapeutics?
Investors of Iambic Therapeutics include Coatue, Abingworth, Illumina Ventures, Mubadala Capital, Nexus Venture Partners and 15 more.
Who are Iambic Therapeutics's competitors?
Competitors of Iambic Therapeutics include Algorithmic Biologics.
Loading...
Compare Iambic Therapeutics to Competitors
Algorithmic Biologics focuses on molecular diagnostics and discovery through technology in the biotech sector. Their main offerings include a software platform with molecular testing workflows to improve efficiency and accuracy, leveraging AI and molecular computing research. The company primarily serves the healthcare industry, particularly in the areas of genomics research and clinical diagnostics. It was founded in 2021 and is based in Bangaluru, India.
10X Genomics focuses on genomic and spatial analysis technologies in the biotechnology sector. The company provides products for researchers to conduct single cell sequencing and spatial transcriptomics, enabling the study of cellular diversity and gene expression. These tools are used in oncology, immunology, and neuroscience. It was founded in 2012 and is based in Pleasanton, California.
Loading...